PR Newswire TechnologyCodex · 实盘不做把握 9/10
北京时间·🕒 发布 04:05:00时区推断·⟳ 抓取 04:05:23·⚡ 决策 08-04 04:14:52 +9m29s·84.6 天前
Karyopharm向1名新员工授予333份RSU入职激励
333份RSU入职激励属于纳斯达克规则下的例行人事股权披露，金额和稀释量级极小。
📄 原文PR Newswire Technology↗ 原文
Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceuti…
不做 Karyopharm Therapeutics（KPTI.US）
333份RSU入职激励为例行披露且同一催化已处理，不改变收入、利润、管线或融资预期。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-08-03 · 扩散 low · price-in 风险 high ↗
消息传播链
- 公司披露向1名新员工授予333份RSU，按Nasdaq Listing Rule 5635(c)(4)作为入职激励。
- 2026-08-03 20:06 UTC其它search_processed_events非一手已处理消息库命中同一催化并判定不做。
关键理由
- 333份RSU入职激励属于纳斯达克规则下的例行人事股权披露，金额和稀释量级极小。
- 事件不改变Karyopharm的XPOVIO商业化、selinexor管线或现金流预期，无法形成同向事件交易。
- 已处理消息库也命中同一催化：Karyopharm向1名新员工授予333份RSU诱导性股权激励。
工具调用 · 历史记录,结果未知(2 种)
- search_processed_events · 结果未知
- stock_quote · 结果未知
原文全文
展开原文 · 2,106 字
NEWTON, Mass., Aug. 3, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted 333 restricted stock units (RSUs) to one newly-hired employee. This RSU award was granted as of July 31, 2026 (the "Grant Date") pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as an inducement material to the new employee entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.
The RSU award will vest over three years, with 33 1/3% of the shares underlying the RSU award vesting on each of the three consecutive anniversaries of the Grant Date. The vesting of the RSU award is subject to the employee's continued service as an employee of, or other service provider to, Karyopharm through the applicable vesting dates.
About Karyopharm Therapeutics
Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit www.karyopharm.com and follow Karyopharm on LinkedIn and on X at @Karyopharm.
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc.
SOURCE Karyopharm Therapeutics Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。